Ya-Chi Chen, Pharm.D.​

Acting Chief Executive Officer

​​Over 20 years of drug development experience with deep expertise in clinical pharmacology, translational medicine, and precision medicine across oncology, immunology, and antibody-drug conjugates (ADCs).​

Previously held senior leadership roles at Roche, Genentech, Revolution Medicines, and Gilead, contributing to the successful development of key therapies including Tecentriq, Actemra, Giredestrant, and Trodelvy.​

Jukka Muhonen

BD Executive Director​

Over 25 years of international experience in business development, licensing, partnerships, and commercialization, with extensive expertise in global pharmaceutical transactions and strategic collaborations.​

​Previously held leadership roles at Orion Pharma and served as VP of Business Development at Orphagen Pharmaceuticals.​

Wei-Han Lee, Ph.D.​

Senior Director, CMC Technical Operations​

​Over 10 years of pharmaceutical industry experience, specializing in ADC CMC process development, site-specific conjugation technologies, and complex biologics development.

Experienced in process and analytical development from candidate selection through clinical development, with a Ph.D. in Chemistry from National Taiwan University.

David Teng-Yi Huang, Ph.D.​

Senior Director, ADC Enabling Technologies​

​Specializes in next-generation ADC technologies, carbohydrate chemistry, and glycobiology, leading the development of GlycOBI®, ThiOBI®, EndoSymeOBI®, HYPrOBI®, and GlycOBI DUO®.​

​Experienced in advancing multiple clinical and preclinical ADC candidates, with a Ph.D. in Chemistry from National Tsing Hua University.​